{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:21Z","timestamp":1794047481209,"version":"4.8.0"},"reference-count":47,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The treatment of blast phase chronic myeloid leukemia (bpCML) remains a challenge due, at least in part, to drug resistance of leukemia stem cells (LSC). Recent clinical evidence suggests that the BCL-2 inhibitor venetoclax in combination with ABL-targeting tyrosine kinase inhibitors can eradicate bpCML LSC. In this study, we employed preclinical models of bpCML to investigate the efficacy and underlying mechanism of LSC-targeting with combinations of venetoclax\/tyrosine kinase inhibitors. Transcriptional analysis of LSC exposed to venetoclax and dasatinib revealed upregulation of genes involved in lysosomal biology, in particular lysosomal acid lipase A (LIPA), a regulator of free fatty acids. Metabolomic analysis confirmed increased levels of free fatty acids in response to treatment with venetoclax\/dasatinib. Pretreatment of leukemia cells with bafilomycin, a specific lysosome inhibitor, or genetic perturbation of LIPA, resulted in increased sensitivity of leukemia cells to venetoclax\/dasatinib, implicating LIPA in treatment resistance. Importantly, venetoclax\/dasatinib treatment did not affect normal stem cell function, suggesting a leukemia-specific response. These results demonstrate that venetoclax\/dasatinib is a LSC-selective regimen in bpCML and that disrupting LIPA and fatty acid transport enhances the response to venetoclax\/ dasatinib when targeting LSC, providing a rationale for exploring lysosomal disruption as an adjunctive therapeutic strategy to prolong disease remission.<\/jats:p>","DOI":"10.3324\/haematol.2023.284716","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T04:38:34Z","timestamp":1719463114000},"page":"103-116","source":"Crossref","is-referenced-by-count":4,"title":["Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax\/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia"],"prefix":"10.3324","volume":"110","author":[{"given":"Mohd","family":"Minhajuddin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Winters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haobin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Gillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krysta","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Gipson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Ransom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Amaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anagha","family":"Inguva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Gasparetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Althoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regan","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter","family":"Tolison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Krug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Culp-Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"D\u2019Alessandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W","family":"Sherbenou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Pollyea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig T","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"70856","doi-asserted-by":"crossref","unstructured":"de Klein A, van Kessel AG, Grosveld G. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1982; 300(5894):765-767.","DOI":"10.1038\/300765a0"},{"key":"70857","doi-asserted-by":"crossref","unstructured":"Fialkow PJ, Denman AM, Jacobson RJ, Lowenthal MN. Chronic myelocytic leukemia. Origin of some lymphocytes from leukemic stem cells. J Clin Invest. 1978; 62(4):815-823.","DOI":"10.1172\/JCI109193"},{"key":"70858","doi-asserted-by":"crossref","unstructured":"Jamieson CH, Ailles LE, Dylla SJ. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004; 351(7):657-667.","DOI":"10.1056\/NEJMoa040258"},{"key":"70859","doi-asserted-by":"crossref","unstructured":"Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344(14):1084-1086.","DOI":"10.1056\/NEJM200104053441409"},{"key":"70860","doi-asserted-by":"crossref","unstructured":"Mahon FX, Rea D, Guilhot J. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11(11):1029-1035.","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"70861","doi-asserted-by":"crossref","unstructured":"Hehlmann R, Saussele S, Voskanyan A, Silver RT. Management of CML-blast crisis. Best Pract Res Clin Haematol. 2016; 29(3):295-307.","DOI":"10.1016\/j.beha.2016.10.005"},{"key":"70862","doi-asserted-by":"crossref","unstructured":"O\u2019Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007; 110(7):2242-2249.","DOI":"10.1182\/blood-2007-03-066936"},{"key":"70863","doi-asserted-by":"crossref","unstructured":"Soverini S, Colarossi S, Gnani A. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006; 12(24):7374-7379.","DOI":"10.1158\/1078-0432.CCR-06-1516"},{"key":"70864","doi-asserted-by":"crossref","unstructured":"Soverini S, Iacobucci I, Baccarani M. Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. Haematologica. 2007; 92(4):437-439.","DOI":"10.3324\/haematol.11248"},{"key":"70865","doi-asserted-by":"crossref","unstructured":"Huang WS, Metcalf CA, Sundaramoorthi R. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl} benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-Abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem. 2010; 53(12):4701-4719.","DOI":"10.1021\/jm100395q"},{"key":"70866","doi-asserted-by":"crossref","unstructured":"Hughes TP, Mauro MJ, Cortes JE. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019; 381(24):2315-2326.","DOI":"10.1056\/NEJMoa1902328"},{"key":"70867","doi-asserted-by":"crossref","unstructured":"Jain P, Kantarjian H, Jabbour E. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematol. 2015; 2(9):e376-383.","DOI":"10.1016\/S2352-3026(15)00127-1"},{"key":"70868","doi-asserted-by":"crossref","unstructured":"Jain P, Kantarjian HM, Ghorab A. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients. Cancer. 2017; 123(22):4391-4402.","DOI":"10.1002\/cncr.30864"},{"key":"70869","doi-asserted-by":"crossref","unstructured":"Hata AN, Engelman JA, Faber AC. The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics. Cancer Discov. 2015; 5(5):475-487.","DOI":"10.1158\/2159-8290.CD-15-0011"},{"key":"70870","doi-asserted-by":"crossref","unstructured":"Beurlet S, Omidvar N, Gorombei P. BCL-2 inhibition with ABT-737 prolongs survival in an NRAS\/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood. 2013; 122(16):2864-2876.","DOI":"10.1182\/blood-2012-07-445635"},{"key":"70871","doi-asserted-by":"crossref","unstructured":"Lagadinou ED, Sach A, Callahan K. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013; 12(3):329-341.","DOI":"10.1016\/j.stem.2012.12.013"},{"key":"70872","doi-asserted-by":"crossref","unstructured":"Quintas-Cardama A, Qiu YH, Post SM. Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment. Cancer. 2012; 118(21):5283-5292.","DOI":"10.1002\/cncr.27568"},{"key":"70873","doi-asserted-by":"crossref","unstructured":"Aichberger KJ, Mayerhofer M, Krauth MT. Identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood. 2005; 105(8):3303-3311.","DOI":"10.1182\/blood-2004-02-0749"},{"key":"70874","doi-asserted-by":"crossref","unstructured":"Horita M, Andreu EJ, Benito A. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med. 2000; 191(6):977-984.","DOI":"10.1084\/jem.191.6.977"},{"key":"70875","doi-asserted-by":"crossref","unstructured":"Pollyea DA, Stevens BM, Jones CL. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018; 24(12):1859-1866.","DOI":"10.1038\/s41591-018-0233-1"},{"key":"70876","doi-asserted-by":"crossref","unstructured":"Carter BZ, Mak PY, Mu H. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med. 2016; 8(355):355ra117.","DOI":"10.1126\/scitranslmed.aag1180"},{"key":"70877","doi-asserted-by":"crossref","unstructured":"Maiti A, Franquiz MJ, Ravandi F. Venetoclax and BCR-ABL tyrosine kinase inhibitor combinations: outcome in patients with Philadelphia chromosome-positive advanced myeloid leukemias. Acta Haematol. 2020; 143(6):567-573.","DOI":"10.1159\/000506346"},{"key":"70878","doi-asserted-by":"crossref","unstructured":"Dubland JA, Francis GA. Lysosomal acid lipase: at the crossroads of normal and atherogenic cholesterol metabolism. Front Cell Dev Biol. 2015; 3:3.","DOI":"10.3389\/fcell.2015.00003"},{"key":"70879","doi-asserted-by":"crossref","unstructured":"Huang SC, Everts B, Ivanova Y. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. Nat Immunol. 2014; 15(9):846-855.","DOI":"10.1038\/ni.2956"},{"key":"70880","doi-asserted-by":"crossref","unstructured":"O\u2019Sullivan D, van der Windt GJ, Huang SC. Memory CD8(+) T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development. Immunity. 2014; 41(1):75-88.","DOI":"10.1016\/j.immuni.2014.06.005"},{"key":"70881","doi-asserted-by":"crossref","unstructured":"Schlager S, Vujic N, Korbelius M. Lysosomal lipid hydrolysis provides substrates for lipid mediator synthesis in murine macrophages. Oncotarget. 2017; 8(25):40037-40051.","DOI":"10.18632\/oncotarget.16673"},{"key":"70882","doi-asserted-by":"crossref","unstructured":"Tabe Y, Saitoh K, Yang H. Inhibition of FAO in AML cocultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine. Sci Rep. 2018; 8(1):16837.","DOI":"10.1038\/s41598-018-35198-6"},{"key":"70883","doi-asserted-by":"crossref","unstructured":"Stevens BM, Jones CL, Pollyea DA. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat Cancer. 2020; 1(12):1176-1187.","DOI":"10.1038\/s43018-020-00126-z"},{"key":"70884","doi-asserted-by":"crossref","unstructured":"Jones CL, Stevens BM, D\u2019Alessandro A. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell. 2018; 34(5):724-740.","DOI":"10.1016\/j.ccell.2018.10.005"},{"key":"70885","doi-asserted-by":"crossref","unstructured":"Neering SJ, Bushnell T, Sozer S. Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood. 2007; 110(7):2578-2585.","DOI":"10.1182\/blood-2007-02-073031"},{"key":"70886","doi-asserted-by":"crossref","unstructured":"Pei S, Pollyea DA, Gustafson A. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020; 10(4):536-551.","DOI":"10.1158\/2159-8290.CD-19-0710"},{"key":"70887","doi-asserted-by":"crossref","unstructured":"Ye H, Minhajuddin M, Krug A. The hepatic microenvironment uniquely protects leukemia cells through induction of growth and survival pathways mediated by LIPG. Cancer Discov. 2021; 11(2):500-519.","DOI":"10.1158\/2159-8290.CD-20-0318"},{"key":"70888","doi-asserted-by":"crossref","unstructured":"Ashton JM, Balys M, Neering SJ. Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells. Cell Stem Cell. 2012; 11(3):359-372.","DOI":"10.1016\/j.stem.2012.05.024"},{"key":"70889","doi-asserted-by":"crossref","unstructured":"Ye H, Adane B, Khan N. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell Stem Cell. 2016; 19(1):23-37.","DOI":"10.1016\/j.stem.2016.06.001"},{"key":"70890","doi-asserted-by":"crossref","unstructured":"Abraham SA. Biological analysis of human CML stem cells; xenograft model of chronic phase human chronic myeloid leukemia. Methods Mol Biol. 2016; 1465:175-185.","DOI":"10.1007\/978-1-4939-4011-0_15"},{"key":"70891","doi-asserted-by":"crossref","unstructured":"Brunetti L, Gundry MC, Kitano A, Nakada D, Goodel MA. Highly efficient gene disruption of murine and human hematopoietic progenitor cells by CRISPR\/Cas9. J Vis Exp. 2018; 134:57278.","DOI":"10.3791\/57278-v"},{"key":"70892","doi-asserted-by":"crossref","unstructured":"Farge T, Saland E, de Toni F. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 2017; 7(7):716-735.","DOI":"10.1158\/2159-8290.CD-16-0441"},{"key":"70893","doi-asserted-by":"crossref","unstructured":"Schlaepfer IR, Joshi M. CPT1A-mediated fat oxidation, mechanisms, and therapeutic potential. Endocrinology. 2020; 161(2):bqz046.","DOI":"10.1210\/endocr\/bqz046"},{"key":"70894","doi-asserted-by":"crossref","unstructured":"Holyoake TL, Vetrie D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood. 2017; 129(12):1595-1606.","DOI":"10.1182\/blood-2016-09-696013"},{"key":"70895","doi-asserted-by":"crossref","unstructured":"Huang W, Luan CH, Hjort EE. The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia. Leukemia. 2016; 30(7):1502-1509.","DOI":"10.1038\/leu.2016.66"},{"key":"70896","doi-asserted-by":"crossref","unstructured":"Mughal TI, Radich JP, Deininger MW. Chronic myeloid leukemia: reminiscences and dreams. Haematologica. 2016; 101(5):541-558.","DOI":"10.3324\/haematol.2015.139337"},{"key":"70897","doi-asserted-by":"crossref","unstructured":"Schmitt MW, Pritchard JR, Leighow SM. Single-molecule sequencing reveals patterns of preexisting drug resistance that suggest treatment strategies in Philadelphia-positive leukemias. Clin Cancer Res. 2018; 24(21):5321-5334.","DOI":"10.1158\/1078-0432.CCR-18-0167"},{"key":"70898","doi-asserted-by":"crossref","unstructured":"Etienne G, Guilhot J, Rea D. Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017; 35(3):298-305.","DOI":"10.1200\/JCO.2016.68.2914"},{"key":"70899","doi-asserted-by":"crossref","unstructured":"Ross DM, Branford S, Seymour JF. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013; 122(4):515-522.","DOI":"10.1182\/blood-2013-02-483750"},{"key":"70900","doi-asserted-by":"crossref","unstructured":"Ito S, Pophali P, Co W. CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML. Bone Marrow Transplant. 2013; 48(10):1313-1316.","DOI":"10.1038\/bmt.2013.49"},{"key":"70901","doi-asserted-by":"crossref","unstructured":"Matte-Martone C, Liu J, Zhou M. Differential requirements for myeloid leukemia IFN-gamma conditioning determine graft-versus-leukemia resistance and sensitivity. J Clin Invest. 2017; 127(7):2765-2776.","DOI":"10.1172\/JCI85736"},{"key":"70902","doi-asserted-by":"crossref","unstructured":"Lulla PD, Naik S, Vasileiou S. Clinical effects of administering leukemia-specific donor T cells to patients with AML\/MDS after allogeneic transplant. Blood. 2021; 137(19):2585-2597.","DOI":"10.1182\/blood.2020009471"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284716\/77239","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284716\/77943","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11664\/77239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:47Z","timestamp":1794046007000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284716","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,27]]}}}